Menu Search
Equities

Frontier Biotechnologies Inc

688221:SHH

Frontier Biotechnologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)7.43
  • Today's Change-0.09 / -1.20%
  • Shares traded5.47m
  • 1 Year change-33.36%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Frontier Biotechnologies Inc grew revenues 34.82% from 84.74m to 114.25m while net income improved from a loss of 356.76m to a smaller loss of 328.96m.
Gross margin33.62%
Net profit margin-209.43%
Operating margin-209.08%
Return on assets-13.31%
Return on equity-21.72%
Return on investment-16.40%
More ▼

Cash flow in CNYView more

In 2023, Frontier Biotechnologies Inc did not generate a significant amount of cash. However, Cash Flow from Investing totalled 172.70m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 267.17m for operations while cash generated from financing totalled 70.29m.
Cash flow per share--
Price/Cash flow per share--
Book value per share3.07
Tangible book value per share2.60
More ▼

Balance sheet in CNYView more

Frontier Biotechnologies Inc has a Debt to Total Capital ratio of 28.08%, a higher figure than the previous year's 7.87%.
Current ratio2.14
Quick ratio2.02
Total debt/total equity0.3904
Total debt/total capital0.2808
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.